enGene Holdings Inc. (ENGN)

enGene announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 in February 2026. In January 2026, the company announced an expanded $125 million debt facility with Hercules Capital, Inc. In December 2025, enGene reported its full-year 2025 financial results, provided a business update, and announced detalimogene's selection for the FDA's CMC Development and Readiness Pilot (CDRP) Program. In November 2025, enGene presented at the Piper Sandler 37th Annual Healthcare Conference and announced the pricing of a $130 million public offering. In September 2025, enGene reported its third-quarter 2025 financial results, achieved target enrollment for the LEGEND trial, and received RMAT designation from the FDA for detalimogene. ENGN shares have seen a 52-week high of $12.25 and a 52-week low of $2.65, and as of February 5, 2026, the closing stock price was $8.86. The stock has drifted +67.3% higher following its earnings release on September 11, 2025.

As a clinical-stage biotechnology company, enGene Holdings, Inc. does not currently have commercialized products or services subject to traditional demand seasonality. Its revenue and operational activities are driven by research milestones, clinical trial progress, and financing activities rather than seasonal consumer demand.

enGene Holdings, Inc. is a clinical-stage biotechnology company focused on mainstreaming genetic medicine through non-viral delivery of therapeutics. The company operates in the Professional, Scientific, and Technical Services sector, specifically in biotechnology research and development. Its core technology is the Dually Derivatized Oligochitosan (DDX) platform, which facilitates localized delivery of genetic cargos. The lead product candidate, detalimogene voraplasmid (EG-70), is an investigational non-viral gene therapy for high-risk non-muscle invasive bladder cancer (NMIBC). Detalimogene is designed to be instilled directly into the bladder to elicit a localized anti-tumor immune response.

enGene Holdings Inc. is incorporated in British Columbia, Canada, with a listed address in Saint-Laurent, Quebec, Canada. The company's common shares trade on The Nasdaq Stock Market LLC under the ticker symbol ENGN. The company also has offices in Boston and Montreal.

enGene Holdings, Inc. maintains a reputation as a clinical-stage biotechnology company focused on addressing diseases with high clinical needs, particularly in urological cancers. Positive developments include achieving target enrollment in the LEGEND trial and receiving RMAT designation from the FDA for detalimogene. Detalimogene was also selected for the FDA's CMC Development and Readiness Pilot Program. However, enGene faces inherent business risks related to its limited experience in conducting later-stage and pivotal clinical trials, which are crucial for regulatory approval.

enGene Holdings Inc. has significant institutional ownership, with 46 institutional owners and shareholders holding 40,969,175 shares, representing 64.16% of the stock. Major institutional shareholders include Fcpm Iii Services B.V., VR Adviser, LLC, Kynam Capital Management, LP, Blue Owl Capital Holdings LP, Cormorant Asset Management, LP, Braidwell Lp, Deep Track Capital, LP, Perceptive Advisors Llc, Point72 Asset Management, L.P., and Frazier Life Sciences Management, L.P. Private equity firms hold approximately 38% of the company's shares, and the top 7 shareholders collectively own about 54% of the company. Insider ownership is also present.